These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 15259182)
1. Droperidol and the black box warning. van Zwieten K; Mullins ME; Jang T Ann Emerg Med; 2004 Jan; 43(1):139-40. PubMed ID: 15259182 [No Abstract] [Full Text] [Related]
2. Droperidol, QT prolongation, and sudden death: what is the evidence? Kao LW; Kirk MA; Evers SJ; Rosenfeld SH Ann Emerg Med; 2003 Apr; 41(4):546-58. PubMed ID: 12658255 [TBL] [Abstract][Full Text] [Related]
3. Unexpected cardiovascular deaths are rare with therapeutic doses of droperidol. Mullins M; Van Zwieten K; Blunt JR Am J Emerg Med; 2004 Jan; 22(1):27-8. PubMed ID: 14724874 [TBL] [Abstract][Full Text] [Related]
4. Evidence-based review of the black-box warning for droperidol. Jackson CW; Sheehan AH; Reddan JG Am J Health Syst Pharm; 2007 Jun; 64(11):1174-86. PubMed ID: 17519460 [TBL] [Abstract][Full Text] [Related]
9. Droperidol: should the black box be light gray? Dershwitz M J Clin Anesth; 2002 Dec; 14(8):598-603. PubMed ID: 12565120 [TBL] [Abstract][Full Text] [Related]
10. Droperidol--behind the black box warning. Horowitz BZ; Bizovi K; Moreno R Acad Emerg Med; 2002 Jun; 9(6):615-8. PubMed ID: 12045077 [No Abstract] [Full Text] [Related]
11. After the black box warning: dramatic changes in ED use of droperidol. Jacoby JL; Fulton J; Cesta M; Heller M Am J Emerg Med; 2005 Mar; 23(2):196. PubMed ID: 15765344 [No Abstract] [Full Text] [Related]
12. Black-box warning for droperidol surprises pharmacists. Young D Am J Health Syst Pharm; 2002 Mar; 59(6):494, 497, 502-4. PubMed ID: 11908241 [No Abstract] [Full Text] [Related]
13. FDA use of the black box warning: time for reevaluation as a safety tool. Liang BA J Clin Anesth; 2002 Dec; 14(8):561-3. PubMed ID: 12565112 [No Abstract] [Full Text] [Related]
14. Does low-dose droperidol administration increase the risk of drug-induced QT prolongation and torsade de pointes in the general surgical population? Nuttall GA; Eckerman KM; Jacob KA; Pawlaski EM; Wigersma SK; Marienau ME; Oliver WC; Narr BJ; Ackerman MJ Anesthesiology; 2007 Oct; 107(4):531-6. PubMed ID: 17893447 [TBL] [Abstract][Full Text] [Related]
15. Safety of droperidol in behavioural emergencies. Shale JH; Shale CM; Mastin WD Expert Opin Drug Saf; 2004 Jul; 3(4):369-78. PubMed ID: 15268653 [TBL] [Abstract][Full Text] [Related]
16. Inside the black box: current policies and concerns with the United States Food and Drug Administration's highest drug safety warning system. Halloran K; Barash PG Curr Opin Anaesthesiol; 2010 Jun; 23(3):423-7. PubMed ID: 20446348 [TBL] [Abstract][Full Text] [Related]
17. A review of the safety and efficacy of droperidol for the rapid sedation of severely agitated and violent patients. Shale JH; Shale CM; Mastin WD J Clin Psychiatry; 2003 May; 64(5):500-5. PubMed ID: 12755651 [TBL] [Abstract][Full Text] [Related]
18. FDA advisory panel discusses droperidol concerns. Young D Am J Health Syst Pharm; 2004 Feb; 61(3):219-20, 222. PubMed ID: 14986550 [No Abstract] [Full Text] [Related]
19. Reviewing case reports and the droperidol warning: FDA response. Chang N; Simone A; Schultheis L; Rappaport B Anesth Analg; 2003 Nov; 97(5):1542. PubMed ID: 14570686 [No Abstract] [Full Text] [Related]
20. Pro: The Food and Drug Administration Black box warning on droperidol is not justified. Habib AS; Gan TJ Anesth Analg; 2008 May; 106(5):1414-7. PubMed ID: 18420854 [No Abstract] [Full Text] [Related] [Next] [New Search]